Ignite Creation Date:
2024-05-06 @ 3:03 PM
Last Modification Date:
2024-10-26 @ 1:41 PM
Study NCT ID:
NCT04500717
Status:
UNKNOWN
Last Update Posted:
2020-08-05
First Post:
2020-08-02
Brief Title:
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Organization Data
Organization:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Class:
OTHER
Study ID:
HS-LK-2020-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Cancer Institute and Hospital Chinese Academy of Medical Sciences
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Jiangsu Hansoh Pharmaceutical Co Ltd | INDUSTRY |